Britain's GlaxoSmithKline has asked its shareholders to vote at a meeting on Dec. 18 on its proposed major deal with Switzerland's Novartis, which will see the two pharmaceutical group trade more than $20 billion of assets. The transaction, which includes GSK buying Novartis' vaccines business, Novartis purchasing GSK's cancer drugs, and the two groups tying up in consumer healthcare, was unveiled in April.